Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy (Q73625614)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

Ursula Denison

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Jose Baumann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Christian Peters-Engl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Hellmut Samonigg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Peter Krippl

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Alois Lang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Helga Wagner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Paul Sevelda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

347-353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12846419%20AND%20SRC:MED&resulttype=core&format=json

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021

Anemia in oncology practice: relation to diseases and their therapies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1024016508925

7 January 2021